What is the most appropriate regimen for untreated Waldenström macroglobulinemia?
- Author:
Naohiro SEKIGUCHI
1
;
Airi HAMANO
;
Tomoko KITAGAWA
;
Kenichi ITO
;
Kazuhiko HIRANO
;
Kazuaki YAMADA
Author Information
- Publication Type:Brief Communication
- MeSH: Cost-Benefit Analysis; Rituximab; Waldenstrom Macroglobulinemia
- From:Blood Research 2019;54(2):153-156
- CountryRepublic of Korea
- Language:English
- Abstract: No abstract available.
